DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financi...(2550463 2812825 Prepaid and ot...),Health

Date:8/11/2009

2,550,463 2,812,825 Prepaid and other current assets 1,341,263 1,718,073 --------- --------- TOTAL CURRENT ASSETS 21,968,841 25,937,932 Restricted cash 174,080 173,844 Property, plant and equipment, net 1,773,485 1,937,978 Deferred charges and other assets 68,099 160,700 ------ ------- TOTAL ASSETS $23,984,505 $28,210,454 =========== =========== LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $466,984 $305,734 Accrued compensation 497,848 1,515,912 Other accrued expenses 2,423,767 3,226,571 Deferred revenue 717,897 611,602 ------- ------- TOTAL CURRENT LIABILITIES 4,106,496 5,659,819 Deferred revenues 3,633,727 4,157,305 Warrant liability 498,188 436,458 Other liabilities 144,069 244,673 ------- ------- TOTAL LIABILITIES 8,382,480 10,498,255 SHAREHOLDERS' EQUITY Capital stock 151,683,399 151,663,943 Authorized: 100,000,000 shares; 40,000,000 shares designated as common stock, no par, and 60,000,000 shares issuable in series or classes; and 40,000 junior Series A preferred shares. Issued and outstanding: 24,108,908 and 24,089,452 shares of common stock, no par, at June 30, 2009 and December 31, 2008, respectively Additional pa
'/>"/>

SOURCE DUSA Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals